

Allfunds announces up to €10m share buyback programme for employees Long-Term Incentive Plan

London/Madrid/Amsterdam – Allfunds Group plc (“Allfunds”) (TICKER: ALLFG), one of the world’s leading B2B WealthTech platforms for the fund industry, announces today the start of a share buyback programme to repurchase its ordinary shares (the “Shares”), with a maximum of up to 1.5 million Shares (“Maximum Shares”) and up to a maximum total value of €10 million (“Maximum Consideration”) on Euronext Amsterdam.

The share buyback programme will commence today and is expected to end at the earliest of: (a) the date on which all the Maximum Shares have been purchased; (b) the date on which the Maximum Consideration has been reached; and (c) 15 December 2022. The Shares will be held in treasury by Allfunds given the purpose of the share buyback programme is to satisfy the needs of the Long-Term Incentive Plan awards for the coming years.

This share buyback programme is being executed pursuant to the authority granted by the shareholders of Allfunds at its annual general meeting held on 21 April 2022, which generally and unconditionally authorised Allfunds to make purchases of up to 62,942,634 of its Shares for the purposes of, or pursuant to, an employees’ share scheme (the “AGM Approval”). It will also be executed in compliance with the requirements under Article 5 of the Market Abuse Regulation (EU) 596/2014 and Article 3 of Commission Delegated Regulation (EU) 2016/1052 (the “Applicable Regulations”). Allfunds has appointed Exane SA (“Exane”) as financial intermediary to conduct the buyback independently and in its sole discretion.

Pursuant to the AGM Approval and Applicable Regulations, the price paid for each Share repurchased as part of the share buyback programme shall not be less than €0.0025, and shall not be higher than (i) an amount equal to 5% above the average market value of a Share for the five business days immediately preceding the day on which Exane agrees to buy the relevant Share as part of the share buyback programme, based on the closing price of each Share on Euronext Amsterdam; and (ii) the higher of the price of the last independent trade on Euronext Amsterdam and the highest current independent purchase bid on Euronext Amsterdam. In addition, Exane will not purchase on any trading day more than 25% of the average daily volume of the Shares on Euronext Amsterdam, based on the average daily volume calculated over the 20 trading days preceding the date of purchase, and no orders will be placed during an auction phase and the orders placed before the start of the auction phase shall not be modified during that phase.

In accordance with the requirements under the Applicable Regulations, Allfunds will provide weekly updates on the progress of the programme via press release and on the Investor Relations section of Allfunds’ website: https://investors.allfunds.com/share_info#share_programme.

Contacts

For media enquiries:

Katherine Sloan, Head of Marketing and Communications
+34 91 274 64 00
katherine.sloan@allfunds.com

For investor enquiries:

Allfunds Group Investor Relations
+34 91 274 64 00
investors@allfunds.com

Important Legal Information

This press release is issued in connection with the disclosure and reporting obligation set out in Article 2(1) of the Commission Delegated Regulation (EU) 2016/1052.

Certain statements in this document may be forward-looking. There are a number of risks, uncertainties and other important factors which could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These include, among other factors, changing economic, business or other market conditions, changing political conditions and the prospects for growth anticipated by the management of Allfunds. Any forward-looking statements contained in this document based upon past trends or activities should not be taken as a representation that such trends or activities will continue in the future. Allfunds does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. No undue reliance should be placed in such forward-looking statements.